PMID- 37266479
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230604
IS  - 1841-9038 (Print)
IS  - 2069-6116 (Electronic)
IS  - 1841-9038 (Linking)
VI  - 18
IP  - 1
DP  - 2023 Mar
TI  - Clinicopathological Study of Breast Carcinoma Patients with Equivocal HER2 
      Immunohistochemical Status: Five-Year Experience from a Tertiary Care Center.
PG  - 27-34
LID - 10.26574/maedica.2023.18.1.27 [doi]
AB  - Background and objectives: Assessment of HER2 gene status has central role in the 
      management of breast cancer patients. For determining HER2 status, 
      immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are the 
      most commonly used tests. Immunohistochemistry scores of 3+ and 1+ were 
      considered as HER2 positive and negative, respectively. On the other hand, HER2 
      equivocal cases need further confirmation by FISH test assessment. This study 
      aimed to identify the clinicopathological characteristics of patients with HER2 
      equivocal tumors served by Sultan Qaboos University Hospital (SQUH) in Muscat, 
      Oman, with emphasis on treatment plans and disease outcome. Methods: This was a 
      retrospective cross-sectional study, which involved all breast cancer female 
      patients who were referred to SQUH from 2016 to 2020. It included a total of 108 
      patients who were diagnosed with HER2 (2+) breast cancer. Patients' data were 
      analyzed in relation to the subsequent FISH status. Results: During the study 
      period, data from 108 females with HER2 2+ were collected; among them, 22 (20%) 
      were FISH positive, 64 (59%) FISH negative, 17 (16%) FISH borderline and five 
      (5%) with no results. Regarding patients' characteristics, 91.2% of all subjects 
      had invasive ductal carcinoma, 93.2% expressed estrogen receptors and 77.6% 
      progesterone receptor. Age, postmenopausal histopathology, tumor grade, TNM 
      staging, ER, PR, Ki67, LVSI, NLR, treatment and follow-up did not show 
      significant association with different FISH results. Conclusions: The majority of 
      HER2 equivocal breast cancer cases were FISH negative. In trastuzumab 
      chemotherapy, an association between different FISH results was expected.
FAU - Al-Zadjali, Yaqeen
AU  - Al-Zadjali Y
AD  - Pathology Department, College of Medicine and Health Sciences, Sultan Qaboos 
      University and Sultan Qaboos University hospital, Oman.
FAU - Al-Rashdi, Afrah
AU  - Al-Rashdi A
AD  - Pathology Department, College of Medicine and Health Sciences, Sultan Qaboos 
      University and Sultan Qaboos University hospital, Oman.
FAU - Al-Husaini, Samya
AU  - Al-Husaini S
AD  - Pathology Department, College of Medicine and Health Sciences, Sultan Qaboos 
      University and Sultan Qaboos University hospital, Oman.
FAU - Al-Badi, Suaad
AU  - Al-Badi S
AD  - Pathology Department, College of Medicine and Health Sciences, Sultan Qaboos 
      University and Sultan Qaboos University hospital, Oman.
FAU - Al-Badi, Hajer
AU  - Al-Badi H
AD  - Pathology Department, College of Medicine and Health Sciences, Sultan Qaboos 
      University and Sultan Qaboos University hospital, Oman.
FAU - Arafa, Mohammad
AU  - Arafa M
AD  - Pathology Department, College of Medicine and Health Sciences, Sultan Qaboos 
      University and Sultan Qaboos University hospital, Oman.
LA  - eng
PT  - Editorial
PL  - Romania
TA  - Maedica (Bucur)
JT  - Maedica
JID - 101526930
PMC - PMC10231159
EDAT- 2023/06/02 13:15
MHDA- 2023/06/02 13:16
PMCR- 2023/03/01
CRDT- 2023/06/02 11:00
PHST- 2023/06/02 13:16 [medline]
PHST- 2023/06/02 13:15 [pubmed]
PHST- 2023/06/02 11:00 [entrez]
PHST- 2023/03/01 00:00 [pmc-release]
AID - 10.26574/maedica.2023.18.1.27 [doi]
PST - ppublish
SO  - Maedica (Bucur). 2023 Mar;18(1):27-34. doi: 10.26574/maedica.2023.18.1.27.